Recent Advances in Clinical Allergy and Immunology

Dagmar Simon

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Keywords

Allergic rhinitis · Bronchial asthma · Angioedema · Atopic dermatitis · Drug hypersensitivity · Food allergy · Urticaria

Abstract

Allergic diseases are of great concern because of their high prevalence, which is still rising in several regions, their impact on patients' physical and psychological health, the huge burden they place on patients' quality of life, as well as the socioeconomic consequences that they cause. Recent research has provided new data on both genetic and environmental risk factors of atopic/allergic diseases. The application of new technologies such as "omics" has allowed a better understanding of the pathogenesis and has helped with the identification of therapeutic targets. Immense progress has been made in developing and applying novel, targeted therapies, for example for asthma and urticaria. Intensive efforts are being made to find biomarkers that help to classify patients, to identify their potential responsiveness to specific therapies, and to monitor the disease severity. Based on recent insights in the pathogenesis of food allergy and drug hypersensitivity, novel strategies for diagnostics, allergen avoidance, and induction of tolerance have been

developed. Here, we summarize important findings in the field of clinical allergy and immunology with a special focus on asthma, allergic rhinitis, atopic dermatitis, food allergy, urticaria, angioedema, and drug hypersensitivity.

© 2018 S. Karger AG, Basel

Introduction

Allergic diseases are common, may seriously affect patients' physical and psychological health and thus exert a huge burden on patients' quality of life as well as on society as a whole. Recent epidemiological studies indicate that the prevalence of such diseases is still increasing in several countries, and reveal new risk factors for the development of atopic/allergic diseases. With the better characterization of the diseases, in particular by applying new technologies such as "omics," it has become obvious that various subgroups exist among these disease entities, for example asthma, allergic rhinitis, atopic dermatitis (AD), and angioedema (AE). Such findings are important

Edited by: H.-U. Simon, Bern.

in view of the development and application of novel, targeted therapies. Intensive efforts are being made to find biomarkers that can help to classify patients, to identify their potential responsiveness to specific therapies, and to monitor the disease severity. In the last few years, new therapies have been studied and approved, such as omalizumab for asthma and urticaria, and these, having now become real-life experiences for patients and clinicians, are providing long-term data. This review summarizes important findings in the field of clinical allergy and immunology.

Toward New Therapies for Asthma

A steady increase in the prevalence of physician-diagnosed asthma, allergic rhinitis, and AD among children aged 6–14 years was reported for Turkey between 1994 and 2014 [1]. The incidence of adult-onset asthma in a population-based cohort in Italy was 4.6% and, interestingly, was not associated with current smoking, though it was greater in ex-smokers compared to never-smokers [2]. In a Brazilian cohort, allergic and nonallergic forms were found to present distinct phenotypes, such as age of onset, rate of intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs), and differing relevant genotypes as shown for HLA class I and II [3].

Asthma is a chronic inflammatory disease that comprises various subgroups with distinct clinical phenotypes, pathomechanisms, and responsiveness to treatment. In order to classify asthma patients and assign them to specific, targeted therapies, biomarkers, and biomarker profiles – for example cytokines involved in asthma pathogenesis – periostin as a marker of eosinophilic inflammation that is IgE specific to certain allergens has become very important [4]. Furthermore, the expression of the interleukin (IL)-33 receptor ST2L on eosinophils, which increases significantly at 24 h postallergen inhalation in allergic asthmatics, might serve as a biomarker and is considered a therapeutic target for asthma [5]. The presence and levels of epithelium-derived cytokines in exhaled-breath condensate have been studied in patients with chronic asthma in order to identify biomarkers for asthma severity. Although thymic stromal lymphopoietin (TSLP) and IL-33 could be detected, confirming their role in asthma pathogenesis, their levels of expression failed to discriminate between controlled and uncontrolled asthma [6].

Respiratory allergy to house dust mites is very common, and thus the recent introduction of sublingually administered allergen immunotherapy tablets (SLIT-tab-

lets) inaugurates a new era for immunotherapy. Despite the fact that biologic material is used to produce the allergen extracts, the standardized production process guarantees high quality and minimal variance between batches [7]. Omalizumab, which has been approved for the treatment of asthma, has excellent short- and long-term effects on asthma outcomes, such as asthma exacerbation and hospitalization rates, as well as with an asthma control test over a period of 5 years [8]. Targeting eosinophils by blocking IL-5 or its receptor is a novel approach for asthma treatment. Benralizumab, an anti-IL-5 receptor antibody, has been demonstrated to significantly reduce the number of asthma exacerbations and to increase the forced expiratory volume in 1s, FEV₁, in an Asian population [9]. Recent observations demonstrate a role for the IL-25/IL-25 receptor axis in asthma, thus also identifying this as a novel therapeutic target [10].

Characterization of Subgroups of Allergic Rhinitis

According to a meta-analysis of 67 cross-sectional studies, the male predominance for development of rhinitis in childhood changes towards a female predominance in adolescence worldwide, except in Asia [11]. In Japanese students, both seasonal and, in particular, perennial allergic rhinitis are significantly associated with a current wheeze [12]. A cross-sectional, observational study investigating real-world practice patterns for allergic rhinitis, asthma, chronic obstructive pulmonary disease, and rhinosinusitis in India, Korea, Malaysia, Singapore, Taiwan, and Thailand provided regional and country-specific information and suggested different practice patterns between specialists and general practitioners, and highlighted the substantial disease burden [13].

An epidemiological survey performed in six cities in France illustrated different sensitization patterns to indoor and outdoor allergens, correlating with geographical location, climate, and environmental exposure [14]. Because of the climate changes and urbanization, ragweed has spread worldwide and has become an important allergen, causing rhinitis and asthma. Immunotherapy to ragweed pollen has been conducted for over 100 years; however, new technologies, such as the application of recombinant allergens, are needed to improve efficacy [15]. Moreover, using new media and building up networks will help to raise awareness and spread information, both to health professionals and to patients [16]. In order to standardize measures of outcome with conjunctival provocation tests, the use of a new scoring protocol, including

the items itching, irritation, tearing, and redness supported by an objective photodocumentation, has been validated [17].

Among grass pollen-allergic children with pollinosis, a subgroup showed a simultaneous sensitization to wheat. Interestingly, wheat sensitization was caused by both cross-reactivity and cosensitization to wheat-specific allergens, and was associated with allergy to staple foods other than wheat [18].

As the nasal provocation test with grass pollen and house dust mites was found to be positive in 25% of non-allergic rhinitis patients, it is strongly recommended to consider and diagnose a local allergic reaction (LAR) [19]. LAR could be confirmed among 25% of adult and 3.4% of pediatric patients with perennial nasal allergy symptoms but a negative skin prick test and an absence of specific IgE antibodies [20, 21]. Whereas house dust mites are the most common cause of LAR in Caucasians, pollens were identified as an important trigger of LAR in China [22].

The clinical relevance of pollen sensitization is mainly determined by major allergens and not by panallergens such as profilin and polcalcin [23]. Chronic allergic sinusitis has been associated with allergy to aeroallergens; however, over 80% of patients with chronic sinusitis are also sensitized to food allergens though without any difference between the groups with and without nasal polyps [24]. In eosinophilic chronic rhinosinusitis (ECRS) the inflammation extends to the lower airways, as indicated by elevated FeNO, and endoscopic sinus surgery may improve both ECRS and pulmonary dysfunction [25]. It is noteworthy that, upon chemotherapy, allergen-specific IgE levels significantly decrease, but do not disappear, suggesting that some plasma cells survive, still producing IgE [26].

Saline nasal irrigation with buffered hypertonic saline as an add-on therapy improves both clinical signs and quality of life in children with seasonal allergic rhinitis and is superior to normal saline solution [27]. Symptoms of dry eyes associated with allergic rhinitis improve upon intranasal corticosteroid therapy, while the intraocular pressure is not affected [28].

Understanding the Pathogenesis of Atopic Dermatitis

Based on novel insights in the pathophysiology of AD, recently developed anti-inflammatory drugs have been designed to specifically target components of the Th2 im-

mune reaction, e.g., IL-13, the IL-4/IL-13 receptor, TSLP, JAK/STAT signaling, CRTH2, and IgE [29]. AD lesions are frequently located in the flexural folds suggesting sweat as a likely trigger. Indeed, skin prick tests to autologous sweat were positive and weakly positive in 38 and 34%, respectively, and correlated with clinical severity, total and specific IgE levels, and sweat tryptase activity [30]. In order to identify biomarkers for AD, stratum corneum tape stripping was applied as a minimally invasive approach for studying local levels of immunomodulatory molecules. CCL17 (TARC) and IL-8 significantly decreased upon therapy in parallel with disease severity [31].

A subgroup of children with AD develop food allergy. Recently, distinct microbial signatures discriminating between ADs with and without food allergy have been identified [32]. The atopy patch test is often used to diagnose food allergy in AD children. A recent study using a freshly prepared puree of cow's milk, egg yolk, egg white, and soy, provided high sensitivity and specificity as well as positive and negative predictive values, illustrating that the atopy patch test is a valuable diagnostic test for food allergy in patients without specific IgE [33]. A recent literature review investigating the efficacy and safety of a partially hydrolyzed whey-based formula in the general population concluded that it supports normal growth in infants, and may reduce the risk of AD in infants who are not fully breastfed as compared to infants receiving a cow's milk formula during the first 4–6 months of life [34]. Another study correlated 25-hydroxyvitamin D levels in umbilical cord blood and serum of infants with the development of allergic sensitization and diseases in early childhood. The authors found no association, thus, the discussion on the role of vitamin D in allergy remains controversial [35]. Unfortunately, exact data on the frequency and role of comorbidities are rare. A systematic review evaluating the association between allergies and hypercholesterolemia did not find conclusive results due to the heterogeneity of studies as well as lack of cross-sectional and prospective studies [36].

Improving the Diagnosis and Treatment of Food Allergy

In a cross-sectional study using a stepwise approach with questionnaires, food allergy was reported to occur in 10.8% of adults, of whom 1.0% were considered to have a positive food allergy diagnosis with reactions to fruits, followed in frequency by reactions against cow's

Fig. 1. Management of food allergy: scheme of diagnostic procedures and therapy.

milk, shrimp, pork, and vegetables [37]. Data for a birth cohort indicate a 2.4% frequency of food allergy as confirmed by oral food challenge (OFC) for infants during the first year of life [38]. In order to study the association between milk and egg allergies and HLA polymorphisms, a bioinformatics approach was applied that mimicked the enzymatic degradation of food allergens and evaluated their binding affinity to DR and/or DQ molecules. Three susceptibility loci for milk and four for egg allergies, as well as four protective alleles for milk allergy, were identified [39].

Cow's milk is the major cause of food allergy in children [38]. For children with cow's milk allergy, amino acid formulas or extensively hydrolyzed formulas should be prescribed as recommended by international guidelines [40]. The risk of developing IgE sensitization to cow's milk has been associated with the duration of breastfeeding and isolated doses of formula feeding in hospital, especially after caesarian delivery [41]. Most children with food allergy develop tolerance, as shown for cow's milk (17/20) and hen's eggs (14/17), by the age of 2 years [42]. Risk factors for a persisting allergy to cow's milk or wheat include having a history of anaphylaxis and high food allergen-specific IgE levels [43, 44].

In order to provide exact dietary recommendations for patients with egg allergy, skin prick tests and measurements of specific IgE should be complemented by OFC tests with raw and heated egg white [45]. Oral immunotherapy with low doses of egg was reported to be effective and safe, and to result in a sustained tolerance in children [46, 47]. Sesame seeds (*Sesamum indicum* L.), buckwheat, and cashew nuts are rare allergens, but all may trigger severe allergic reactions; hence, the indications for any OFC tests should be carefully considered [48–50]. The characterization of Dutch patients with sesame allergy revealed a 14-kDa protein identified as oleosin (Ses i 4 and/or Ses i 5) as the major allergen and, furthermore, the possibility of a cross-reactivity of sesame with various tree nuts [48]. Indicators for a shrimp allergy are high levels of IgE to rPen a 1 and rDer p 10; the presence of a house dust mite-induced asthma and simultaneous IgE to Der p 1, 2, and 10 might help to distinguish between subjects with shrimp allergy and those that are sensitized but tolerant [51].

OFC is the diagnostic gold standard (Fig. 1). It should be considered that OFC tests bear the risk of severe allergic reactions, for which a history of anaphylactic reactions and older age are considered risk factors [52]. Since serum IgE levels to Ara h 2 have both high negative and positive predictive values, the number of OFC needed in suspected peanut allergy can be reduced [53]. In peanut-allergic patients from China, Ara h 9, a nonspecific lipid transfer protein, was identified as a major allergen [54]. Successful oral immunotherapy in children with an anaphylactic peanut allergy has been reported, with all children having achieved desensitization after 8 months, and 15 out of 22 patients maintaining a sustained unresponsiveness after 2 years [55].

In acute reactions of food protein-induced enterocolitis syndrome, an increased expression of CD69 on eosinophils has been noted, though the absolute eosinophil counts in the peripheral blood were not increased, suggesting CD69 as a marker for systemic events in the disease [56]. If patients on oral or sublingual immunotherapy develop gastrointestinal symptoms, they should be evaluated by endoscopy for eosinophilic gastrointestinal disorders [57].

Unraveling Urticaria

Omalizumab, an anti-IgE antibody, is recommended for the therapy of chronic spontaneous urticaria (CSU) refractory to antihistamines used even at 4-fold doses

Table 1. Warning signs for recognizing hereditary angioedema [74]

A	Angioedema
B	Bradykinin mediated
C	C1 inhibitor deficiency
D	Distress factors
E	Epinephrine nonresponsiveness
F	Family history
G	Glottis/gastrointestinal edema

[58]. The real-life experience of omalizumab efficacy shows a complete response in 85 and 60% of patients started on 300 and 150 mg, respectively, and a high safety profile [59]. Upon omalizumab therapy, a decrease in plasma D-dimer levels that had been elevated in 59% of CSU patients at baseline has been noted in responders [60]. CSU patients, in particular those with low plasma D-dimer levels, may benefit from autologous whole-blood injections as an add-on therapy to antihistamines [61]. Patients with low levels of diamine oxidase (DAO), an enzyme that catabolizes and inactivates histamine, slightly improve upon a supplemental therapy with DAO [62].

Despite the fact that coagulation is enhanced in chronic urticaria, the data on the role of platelets in the pathogenesis of CU are limited and conflicting [63]. As blood levels of NO_x and nitrate are significantly higher in CSU patients compared to healthy controls, and correlate with disease activity, a pathogenic role of nitrosative stress has been suggested [64]. A recent study reported a frequent association of CSU with upper gastrointestinal inflammatory disorders with and without *Helicobacter pylori* infection, and an improvement of urticaria in parallel with a successful treatment of the gastrointestinal disorder [65]. In India, *H. pylori* infections, which are mainly asymptomatic, are also frequent in CSU patients; however, the implications for disease course and severity are not clear [66]. Parasites were detected in 10% of children with CSU, of which half responded to an antiparasitic therapy [67].

In order to identify a genetic predisposition to NSAID-induced urticaria/AE, the presence of single-nucleotide polymorphisms in TSLP, IL7R, and TSLPR was investigated, but these were found not to be associated with the disease [68]. Based on the observation that CSU may be associated with a concomitant IgA deficiency (IGAD), a screening for IGAD- and IGAD-associated autoimmune diseases in CSU patients has been recommended [69]. High CD63 values upon basophil activation test have

been recognized in children with CSU correlating with disease severity and possibly discriminating CSU from physical urticaria [70]. Acute urticaria has been reported more often in asthma patients (23%), mainly associated with seasonal asthma exacerbations, compared to 2% in healthy controls, whereas patients with CSU do not show an increased incidence of asthma [71].

The Diagnostic ABC for AE

AE without wheals has long been classified as either hereditary or acquired. Recent research has provided evidence that there is a heterogeneity of pathogenesis and phenotypes that allows a classification of subgroups, the establishment of diagnostic algorithms, and also has implications for treatment [72]. The characterization of patients with recurrent AE without urticaria reveals distinct subgroups based on clinical data and complement screening [73]. In order to diagnose and correctly treat hereditary AE (HAE) to avoid fatalities, an “ABC” for the warning signs of HAE has been developed: A = AE, B = bradykinin, C = C1 inhibitor, D = distress factors, E = epinephrine unresponsive, F = family history, and G = glottis/gastrointestinal edema (Table 1) [74].

Still, the etiology of AE is often difficult to determine, although this may sometimes be essential in emergency situations. A comparison of biomarkers revealed no differences in complement C1 and C4, but peaks of D-dimer levels during attacks and higher circulating VE-cadherin levels in patients with bradykinin- or histamine-mediated AE compared to those with abdominal pain of other causes, have been detected [75]. A shortened activated partial thromboplastin time is more frequently observed in patients with AE due to C1-INH deficiency compared to patients with various forms of AE with normal C1-INH [76]. Since blood levels of endocan and vascular cell adhesion molecules are increased in HAE patients even in attack-free periods, they are considered as markers for endothelial activation and might be able to serve as diagnostic markers [77].

In view of the large heterogeneity in the clinical presentation of hereditary AE due to C1 inhibitor deficiency (C1-INH-HAE), functional polymorphisms of the KLKB1 gene encoding plasma kallikrein and the F12-46C/T polymorphism were studied and showed that carriers of the G-allele of the KLKB1-428G/A polymorphism exhibited a significantly delayed disease onset by 4 years, while carriers of both the KLKB1-428G/A and the F12-46C/T polymorphisms displayed an 8.8-year delay in dis-

Color version available online

Fig. 2. Pathomechanisms of drug hypersensitivity [81].

ease onset and a 64% lower probability of needing long-term prophylactic treatment [78]. In addition, ethnic differences have been detected, indicating a lower prevalence of HAE and involvement of the gastrointestinal tract in Asia as compared to Western countries [79].

Supplementation of C1-INH has been shown to be effective in coping with and preventing attacks in HAE patients. Recently, the efficacy and safety of Cinryze, a nano-filtered human plasma-derived C1-INH, has been proven in children with HAE [80].

Drug Hypersensitivity: The Triad of Pathomechanism, Diagnostic Progress, and Management

Enormous progress has been made in understanding drug hypersensitivity. Three distinct ways by which stimulation of immune or inflammatory cells associated with typical clinical manifestations, time of appearance, dose dependence, predictability, and cross-reactivity have been identified: (a) an allergic/immune reaction; (b) pharmacological interaction with immune receptors (P-I reactions), and (c) pseudo-allergic reaction (Fig. 2) [81]. Multiple drug hypersensitivity is characterized by long-lasting hypersensitivity reactions to different drugs as a consequence of a massive T cell stimulation that first presents with exanthema or drug rash with eosinophilia and systemic symptoms, while upon the second stimulus, erythroderma, Stevens-Johnson syndrome/toxic epidermal necrolysis, hepatitis, and agranulocytosis may develop [82].

In patients with suspected allergy to amoxicillin, skin tests for determinants of amoxicillin and amoxicillin-cla-

vulanate, in addition to major and minor penicillin determinants, are recommended in order to avoid false negative tests, and thus to decrease the need for oral provocation tests [83]. In children with an EBV infection a skin rash developed in 18.6%, of whom 50% were treated with antibiotics. A hypersensitivity reaction to aminopenicillin could be confirmed in 30–50% by drug provocation tests and re-exposure, respectively [84]. Higher comorbidity rates together with longer hospitalization stays have been noted in children with a penicillin allergy label; however, whether this is a cause or a consequence remains unclear [85].

Despite the high incidence of suspected non- β -lactam (NBL) hypersensitivity, the frequency of confirmed hypersensitivity is low, this being the reason why a detailed history should be taken from patients with suspected NBL hypersensitivity; furthermore, drug provocation tests should be performed in patients without contraindications [86]. NSAIDs are the second most frequent drug type to cause hypersensitivity reactions in children, these occurring mainly in children with asthma at a frequency of 1% [87].

Hypersensitivity reactions to NSAIDs, in particular to acetylsalicylic acid, are commonly reported; however, they can be confirmed in only 21% of patients. Clinical presentations are urticarial/AE or anaphylaxis [88]. In the case of NSAID hypersensitivity, those patients requiring dual antiplatelet therapy because of acute cardiovascular events might have to be diagnosed immediately and/or desensitized. A recently published algorithm provides best practice recommendations and has been proven feasible in establishing a safe administration of acetylsalicylic acid in cardiovascular patients with NSAID hypersensitivity with skin and/or respiratory involvement [89].

Pyrazolones are the most common causes of single NSAID-induced hypersensitivity and present as immediate reactions with urticaria/AE and anaphylaxis (60%), or as delayed hypersensitivity reactions such as maculopapular exanthema. A combination of diagnostic procedures including skin tests, basophil activation test, and drug provocation have been recommended to verify or exclude metamizole hypersensitivity [90]. In agreement with this conclusion, acetaminophen, the most commonly used antipyretic in children, should be considered as a possible cause of both immediate, most likely IgE-mediated, and nonimmediate hypersensitivity reactions [91].

The neuromuscular blocking agent rocuronium may cause IgE-mediated anaphylaxis as well as non-IgE-mediated hypersensitivity reactions that can be reversed by sugammadex, suggesting a non-IgE-mediated MRG-

PRX2- (Mas-related G-protein-coupled receptor member X2) triggered mast cell degranulation induced by rocuronium [92]. In cases of rare, immediate-type reactions to heparins that can be identified by skin prick testing, alternative therapies with unfractionated heparins or fondaparinux have been recommended [93].

When used as a tool to diagnose anticonvulsant drug hypersensitivity, the lymphocyte transformation test has a high specificity but a low sensitivity, and provides the most valuable results for the diagnosis of carbamazepine and phenytoin hypersensitivity [94]. A retrospective analysis of hypersensitivity reactions to proton pump inhibitors showed lansoprazole to be the most frequently implicated drug, followed by pantoprazole, esomeprazole, rabeprazole, and omeprazole, as well as anaphylaxis being the most frequent manifestation [95]. Since cross-reactions among proton pump inhibitors may occur, alternative drugs should be included in the diagnostic workup [95]. Rapid desensitization in patients with drug hypersensitivity to biologics, such as rituximab, infliximab, cetuximab, and trastuzumab, for which a detailed protocol has been developed, has been documented as safe and effective [96].

Identifying and Managing Anaphylaxis

As the main causes of anaphylaxis, food, drugs – most commonly NSAIDs – and insect bites have been identified, with 15% remaining idiopathic. Food allergy occurred more often in children, while drug anaphylaxis was more common in adults. There was an age-dependent shift of clinical presentations with gastrointestinal symptoms in infants and young children, respiratory symptoms in schoolchildren and adolescents, and cardiovascular symptoms in adults [97]. A cross-sectional study

revealed symptoms of sting reactions in 13% of the overall population, of which half had systemic reactions. Interestingly, while a sensitization to venom was found in 15% of the population, only 31% of these had reacted to stings, while only 38% of those with sting reactions had IgE to venom. Surprisingly, no increased rate of reaction to stings was found in individuals with serum tryptase above the normal range [98].

Retrospective analyses of the use of epinephrine in anaphylaxis demonstrated a low rate of side effects that were usually mild and transient, and thus do not justify a restriction of adrenaline use in anaphylaxis [99]. Furthermore, underuse, inappropriate IV bolus use, and overdose were identified as major problems with epinephrine use, emphasizing the importance of training for professionals and education for patients [100].

Outlook

Over recent years, research has provided immense progress in understanding the pathomechanisms of allergic diseases and has unraveled new therapeutic approaches. With the development of novel therapies, of which some have already been approved, we face a new era of disease management and, with that, probably a modification of the expected course of diseases. Still, there are a number of unmet needs, for example in understanding the role of genetics and its interaction with the environment, monitoring disease severity, and response to treatment, and for preventing allergic diseases.

Disclosure Statement

The author has no conflicts of interest to declare.

References

- 1 Doğruel D, Bingöl G, Altınbaş DU, Seydaoglu G, Erkan A, Yılmaz M. The Trend of Change of Allergic Diseases over the Years: Three Repeated Surveys from 1994 to 2014. *Int Arch Allergy Immunol*. 2017;173(3):178–82.
- 2 Verlato G, Nguyen G, Marchetti P, Accordini S, Marcon A, Marconcini R, et al. Smoking and New-Onset Asthma in a Prospective Study on Italian Adults. *Int Arch Allergy Immunol*. 2016;170(3):149–57.
- 3 Takejima P, Agondi RC, Rodrigues H, Aun MV, Kalil J, Giavina-Bianchi P. Allergic and Nonallergic Asthma Have Distinct Phenotypic and Genotypic Features. *Int Arch Allergy Immunol*. 2017;172(3):150–60.
- 4 Karaulov AV, Garib V, Garib F, Valenta R. Protein Biomarkers in Asthma. *Int Arch Allergy Immunol*. 2018;175(4):189–208.
- 5 Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, et al. IL-33 and Its Receptor ST2 after Inhaled Allergen Challenge in Allergic Asthmatics. *Int Arch Allergy Immunol*. 2018;176(2):133–42.
- 6 Glück J, Rymarczyk B, Kasprzak M, Rogala B. Increased Levels of Interleukin-33 and Thymic Stromal Lymphopoietin in Exhaled Breath Condensate in Chronic Bronchial Asthma. *Int Arch Allergy Immunol*. 2016;169(1):51–6.
- 7 Henmar H, Frisenette SM, Grosch K, Nielsen K, Smith G, Sønderkær S, et al. Fractionation of Source Materials Leads to a High Reproducibility of the SQ House Dust Mite SLIT-Tablets. *Int Arch Allergy Immunol*. 2016;169(1):23–32.
- 8 Yorgancıoğlu A, Öner Erkeköl F, Mungan D, Erdinç M, Gemicioğlu B, Özşeker ZF, et al. Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial. *Int Arch Allergy Immunol*. 2018;176(3-4):225–33.

- 9 Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A Phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. *Int Arch Allergy Immunol.* 2016;169(3):135–45.
- 10 Tang W, Smith SG, Salter B, Oliveria JP, Mitchell P, Nusca GM, et al. Allergen-Induced Increases in Interleukin-25 and Interleukin-25 Receptor Expression in Mature Eosinophils from Atopic Asthmatics. *Int Arch Allergy Immunol.* 2016;170(4):234–42.
- 11 Pinart M, Keller T, Reich A, Fröhlich M, Cabieses B, Hohmann C, et al. Sex-Related Allergic Rhinitis Prevalence Switch from Childhood to Adulthood: A Systematic Review and Meta-Analysis. *Int Arch Allergy Immunol.* 2017;172(4):224–35.
- 12 Matsumoto M, Konno S, Kimura H, Takei N, Kimura H, Shimizu K, et al. Associations of Current Wheeze and Body Mass Index with Perennial and Seasonal Allergic Rhinitis in Young Adults. *Int Arch Allergy Immunol.* 2018;176(2):143–9.
- 13 Wang Y, Cho SH, Lin HC, Ghoshal AG, Bin Abdul Muttalif AR, Thanaviratananich S, et al. Practice Patterns for Chronic Respiratory Diseases in the Asia-Pacific Region: A Cross-Sectional Observational Study. *Int Arch Allergy Immunol.* 2018;177(1):69–79.
- 14 Charpin D, Ramadour M, Lavaud F, Raherison C, Caillaud D, de Blay F, et al. Climate and Allergic Sensitization to Airborne Allergens in the General Population: Data from the French Six Cities Study. *Int Arch Allergy Immunol.* 2017;172(4):236–41.
- 15 Chen KW, Marusciac L, Tamas PT, Valenta R, Panaiteanu C. Ragweed Pollen Allergy: Burden, Characteristics, and Management of an Imported Allergen Source in Europe. *Int Arch Allergy Immunol.* 2018;176(3-4):163–80.
- 16 Bousquet J, Agache I, Berger U, Bergmann KC, Besancenot JP, Bousquet PJ, et al. Differences in Reporting the Ragweed Pollen Season Using Google Trends across 15 Countries. *Int Arch Allergy Immunol.* 2018;176(3-4):181–8.
- 17 Pfaar O, Claßen DP, Astvatsatourov A, Klimek L, Mösges R. Reliability of a New Symptom Score in a Titrated Quantitative Conjunctival Provocation Test Supported by an Objective Photodocumentation. *Int Arch Allergy Immunol.* 2018;176(3-4):215–24.
- 18 Nilsson N, Nilsson C, Ekoff H, Wieser-Pahr S, Borres MP, Valenta R, et al. Grass-Allergic Children Frequently Show Asymptomatic Low-Level IgE Co-Sensitization and Cross-Reactivity to Wheat. *Int Arch Allergy Immunol.* 2018;177(2):135–44.
- 19 Duman H, Bostanci I, Ozmen S, Dogru M. The Relevance of Nasal Provocation Testing in Children with Nonallergic Rhinitis. *Int Arch Allergy Immunol.* 2016;170(2):115–21.
- 20 Krajewska-Wojtyś A, Jarzab J, Zawadzinska K, Pyrkosz K, Bozek A. Local Allergic Rhinitis in Adult Patients with Chronic Nasal Symptoms. *Int Arch Allergy Immunol.* 2017;173(3):165–70.
- 21 Ha EK, Na MS, Lee S, Baek H, Lee SJ, Sheen YH, et al. Prevalence and clinical characteristics of local allergic rhinitis in children sensitized to house dust mites. *Int Arch Allergy Immunol.* 2017;174(3-4):183–9.
- 22 Tao XY, Ng CL, Chen D, Lin ZB, Wu SL, Liang MJ, et al. Clinical Characteristics and Allergen Sensitization Patterns of Patients with Local Allergic Rhinitis in Southern China. *Int Arch Allergy Immunol.* 2018;175(1-2):107–13.
- 23 San Nicolás M, Braun T, Eder K, Berghaus A, Gröger M. Clinical Relevance of IgE to Profilin and/or Polcalcin in Pollen-Sensitized Patients. *Int Arch Allergy Immunol.* 2016;169(2):101–7.
- 24 Al-Qudah M. Food Sensitization in Medically Resistant Chronic Rhinosinusitis with or without Nasal Polyposis. *Int Arch Allergy Immunol.* 2016;169(1):40–4.
- 25 Kambara R, Minami T, Akazawa H, Tsuji F, Sasaki T, Inohara H, et al. Lower Airway Inflammation in Eosinophilic Chronic Rhinosinusitis as Determined by Exhaled Nitric Oxide. *Int Arch Allergy Immunol.* 2017;173(4):225–32.
- 26 Whiteside S, Markova M, Chin A, Lam C, Dharmani-Khan P, Modi M, et al. Influence of Chemotherapy on Allergen-Specific IgE. *Int Arch Allergy Immunol.* 2018;177(2):145–52.
- 27 Malizia V, Fasola S, Ferrante G, Cilluffo G, Montalbano L, Landi M, et al. Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial. *Int Arch Allergy Immunol.* 2017;174(2):97–103.
- 28 Yenigun A, Elbay A, Dogan R, Ozturan O, Ozdemir MH. A Pilot Study Investigating the Impact of Topical Nasal Steroid Spray in Allergic Rhinitis Patients with Dry Eye. *Int Arch Allergy Immunol.* 2018;176(2):157–62.
- 29 Moreno AS, McPhee R, Arruda LK, Howell MD. Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis. *Int Arch Allergy Immunol.* 2016;171(2):71–80.
- 30 Ilves T, Virolainen A, Harvima IT. Immediate Wheal Reactivity to Autologous Sweat in Atopic Dermatitis Is Associated with Clinical Severity, Serum Total and Specific IgE and Sweat Tryptase Activity. *Int Arch Allergy Immunol.* 2016;170(2):84–91.
- 31 Koppes SA, Brans R, Ljubojevic Hadzavdic S, Frings-Dresen MH, Rustemeyer T, Kezic S. Stratum Corneum Tape Stripping: Monitoring of Inflammatory Mediators in Atopic Dermatitis Patients Using Topical Therapy. *Int Arch Allergy Immunol.* 2016;170(3):187–93.
- 32 Fieten KB, Totté JE, Levin E, Reyman M, Meijer Y, Knulst A, et al. Fecal Microbiome and Food Allergy in Pediatric Atopic Dermatitis: A Cross-Sectional Pilot Study. *Int Arch Allergy Immunol.* 2018;175(1-2):77–84.
- 33 Mansouri M, Rafiee E, Darougar S, Mesdaghi M, Chavoshzadeh Z. Is the Atopy Patch Test Reliable in the Evaluation of Food Allergy-Related Atopic Dermatitis? *Int Arch Allergy Immunol.* 2018;175(1-2):85–90.
- 34 Sauter J, Nutton S, de Groot N, Pecquet S, Simon D, Simon HU, et al. Partially Hydrolyzed Whey Infant Formula: Literature Review on Effects on Growth and the Risk of Developing Atopic Dermatitis in Infants from the General Population. *Int Arch Allergy Immunol.* 2018;177(2):123–34.
- 35 Savilahti EM, Mäkitie O, Kukkonen AK, Andersson S, Viljakainen H, Savilahti E, et al. Serum 25-Hydroxyvitamin D in Early Childhood Is Nonlinearly Associated with Allergy. *Int Arch Allergy Immunol.* 2016;170(3):141–8.
- 36 Manti S, Cuppari C, Marseglia L, D'Angelo G, Arrigo T, Gitto E, et al. Association between Allergies and Hypercholesterolemia: A Systematic Review. *Int Arch Allergy Immunol.* 2017;174(2):67–76.
- 37 Silva LA, Silva AF, Ribeiro AC, Silva AO, Vieira FA, Segundo GR. Adult food allergy prevalence: reducing questionnaire bias. *Int Arch Allergy Immunol.* 2016;171(3-4):261–4.
- 38 Doğruel D, Bingöl G, Altıntaş DU, Yılmaz M, Güneşer Kendirli S. Clinical Features of Food Allergy during the 1st Year of Life: The ADAPAR Birth Cohort Study. *Int Arch Allergy Immunol.* 2016;169(3):171–80.
- 39 Dimitrov I, Doytchinova I. Associations between Milk and Egg Allergens and the HLA-DRB1/DQ Polymorphism: A Bioinformatics Approach. *Int Arch Allergy Immunol.* 2016;169(1):33–9.
- 40 Luyt D, Krishnan MT, Huber P, Clark A. Practice of the Treatment of Milk Allergy in the UK: A National Audit. *Int Arch Allergy Immunol.* 2016;169(1):62–8.
- 41 Gil F, Amezcua A, Martinez D, Aznal E, Etayo V, Durá T, et al. Association between Caesarean Delivery and Isolated Doses of Formula Feeding in Cow Milk Allergy. *Int Arch Allergy Immunol.* 2017;173(3):147–52.
- 42 Doğruel D, Bingöl G, Yılmaz M, Altıntaş DU. The ADAPAR Birth Cohort Study: Food Allergy Results at Five Years and New Insights. *Int Arch Allergy Immunol.* 2016;169(1):57–61.
- 43 Koike Y, Sato S, Yanagida N, Asaumi T, Ogura K, Ohtani K, et al. Predictors of Persistent Milk Allergy in Children: A Retrospective Cohort Study. *Int Arch Allergy Immunol.* 2018;175(3):177–80.
- 44 Koike Y, Yanagida N, Sato S, Asaumi T, Ogura K, Ohtani K, et al. Predictors of Persistent Wheat Allergy in Children: A Retrospective Cohort Study. *Int Arch Allergy Immunol.* 2018;176(3-4):249–54.
- 45 Kido J, Nishi N, Matsumoto T. The Oral Provocation Test for Raw Egg in Patients with Hen Egg Allergy. *Int Arch Allergy Immunol.* 2018;177(1):40–4.
- 46 Yanagida N, Sato S, Asaumi T, Nagakura K, Ogura K, Ebisawa M. Safety and Efficacy of Low-Dose Oral Immunotherapy for Hen's Egg Allergy in Children. *Int Arch Allergy Immunol.* 2016;171(3-4):265–8.

- 47 Maeta A, Matsushima M, Muraki N, Asano M, Takaoka Y, Kameda M, et al. Low-Dose Oral Immunotherapy Using Low-Egg-Allergen Cookies for Severe Egg-Allergic Children Reduces Allergy Severity and Affects Allergen-Specific Antibodies in Serum. *Int Arch Allergy Immunol*. 2018;175(1-2):70–6.
- 48 Teodorowicz M, Terlouw RJ, Jansen A, Savelkoul HF, Ruinemans-Koerts J. Immunological Characterization of Dutch Sesame Seed-Allergic Patients. *Int Arch Allergy Immunol*. 2016;169(1):13–22.
- 49 Yanagida N, Sato S, Takahashi K, Nagakura KI, Ogura K, Asaumi T, et al. Reactions of Buckwheat-Hypersensitive Patients during Oral Food Challenge Are Rare, but Often Anaphylactic. *Int Arch Allergy Immunol*. 2017;172(2):116–22.
- 50 Inoue T, Ogura K, Takahashi K, Nishino M, Asaumi T, Yanagida N, et al. Risk Factors and Clinical Features in Cashew Nut Oral Food Challenges. *Int Arch Allergy Immunol*. 2018;175(1-2):99–106.
- 51 Farioli L, Losappio LM, Giuffrida MG, Pravettoni V, Micarelli G, Nichelatti M, et al. Mite-Induced Asthma and IgE Levels to Shrimp, Mite, Tropomyosin, Arginine Kinase, and Der p 10 Are the Most Relevant Risk Factors for Challenge-Proven Shrimp Allergy. *Int Arch Allergy Immunol*. 2017;174(3-4):133–43.
- 52 Yanagida N, Sato S, Asaumi T, Ogura K, Ebisawa M. Risk Factors for Severe Reactions during Double-Blind Placebo-Controlled Food Challenges. *Int Arch Allergy Immunol*. 2017;172(3):173–82.
- 53 Martinet J, Couderc L, Renosi F, Bobée V, Marguet C, Boyer O. Diagnostic Value of Antigen-Specific Immunoglobulin E Immunoassays against Ara h 2 and Ara h 8 Peanut Components in Child Food Allergy. *Int Arch Allergy Immunol*. 2016;169(4):216–22.
- 54 Ma S, Nie L, Li H, Wang R, Yin J. Component-Resolved Diagnosis of Peanut Allergy and Its Possible Origins of Sensitization in China. *Int Arch Allergy Immunol*. 2016;169(4):241–8.
- 55 Nagakura KI, Sato S, Yanagida N, Nishino M, Asaumi T, Ogura K, et al. Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy. *Int Arch Allergy Immunol*. 2018;175(3):181–8.
- 56 Wada T, Matsuda Y, Toma T, Koizumi E, Okamoto H, Yachie A. Increased CD69 Expression on Peripheral Eosinophils from Patients with Food Protein-Induced Enterocolitis Syndrome. *Int Arch Allergy Immunol*. 2016;170(3):201–5.
- 57 Babaie D, Mesdaghi M, Nishino M, Mansouri M, Ebisawa M. Oral and Sublingual Immunotherapy: Potential Causes for Eosinophilic Gastrointestinal Disorders? *Int Arch Allergy Immunol*. 2017;172(2):89–98.
- 58 Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. *Allergy*. 2018;73:1393–414.
- 59 Ensina LF, Valle SO, Juliani AP, Galeane M, Vieira dos Santos R, Arruda LK, et al. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience. *Int Arch Allergy Immunol*. 2016;169(2):121–4.
- 60 Asero R, Marzano AV, Ferrucci S, Cugno M. D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria. *Int Arch Allergy Immunol*. 2017;172(1):40–4.
- 61 Kitsioulis NA, Xepapadaki P, Roussaki-Schulze AV, Papadopoulos N, Zafiriou E. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria. *Int Arch Allergy Immunol*. 2017;172(3):161–6.
- 62 Yacoub MR, Ramirez GA, Berti A, Mercurio G, Breda D, Saporiti N, et al. Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study. *Int Arch Allergy Immunol*. 2018;176(3-4):268–71.
- 63 Vena GA, Cassano N, Marzano AV, Asero R. The Role of Platelets in Chronic Urticaria. *Int Arch Allergy Immunol*. 2016;169(2):71–9.
- 64 Dilek F, Ozceker D, Ozkaya E, Guler EM, Yazici M, Tamay Z, et al. Elevated Nitrosative Stress in Children with Chronic Spontaneous Urticaria. *Int Arch Allergy Immunol*. 2017;172(1):33–9.
- 65 Zheleznov S, Urzhumtseva G, Petrova N, Sarsaniia Z, Didkovskii N, Dörr T, et al. Gastritis Can Cause and Trigger Chronic Spontaneous Urticaria Independent of the Presence of *Helicobacter pylori*. *Int Arch Allergy Immunol*. 2018;175(4):246–51.
- 66 Kohli S, Mahajan VK, Rana BS, Mehta KS, Raina RK, Chauhan PS, et al. Clinicopathologic Features of Chronic Urticaria in Patients with versus without Subclinical *Helicobacter pylori* Infection: A Cross-Sectional Study of 150 Patients. *Int Arch Allergy Immunol*. 2018;175(1-2):114–20.
- 67 Arik Yilmaz E, Karaatmaca B, Sackesen C, Sahiner UM, Cavkaytar O, Sekerel BE, et al. Parasitic Infections in Children with Chronic Spontaneous Urticaria. *Int Arch Allergy Immunol*. 2016;171(2):130–5.
- 68 Plaza-Serón MC, Blanca-López N, Pérez-Sánchez N, Doña I, Acosta-Herrera M, Pino-Yanes M, et al. Genetic Variants of Thymic Stromal Lymphopoietin in Nonsteroidal Anti-Inflammatory Drug-Induced Urticaria/Angioedema. *Int Arch Allergy Immunol*. 2016;169(4):249–55.
- 69 Frossi B, De Carli S, Bossi F, Pucillo C, De Carli M. Co-Occurrence of Chronic Spontaneous Urticaria with Immunoglobulin A Deficiency and Autoimmune Diseases. *Int Arch Allergy Immunol*. 2016;169(2):130–4.
- 70 Netchiporouk E, Moreau L, Rahme E, Maurer M, Leitenyi D, Ben-Shoshan M. Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease Activity. *Int Arch Allergy Immunol*. 2016;171(2):81–8.
- 71 Vadasz Z, Kessel A, Hershko AY, Maurer M, Toubi E. Seasonal Exacerbation of Asthma Is Frequently Associated with Recurrent Episodes of Acute Urticaria. *Int Arch Allergy Immunol*. 2016;169(4):263–6.
- 72 Bova M, De Feo G, Parente R, De Pasquale T, Gravante C, Pucci S, et al. Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes. *Int Arch Allergy Immunol*. 2018;175(3):126–35.
- 73 Triggianese P, Guarino MD, Pellicano C, Borzi M, Greco E, Modica S, et al. Recurrent Angioedema: Occurrence, Features, and Concomitant Diseases in an Italian Single-Center Study. *Int Arch Allergy Immunol*. 2017;172(1):55–63.
- 74 Grumach AS, Ferraroni N, Olivares MM, López-Serrano MC, Bygum A. An ABC of the Warning Signs of Hereditary Angioedema. *Int Arch Allergy Immunol*. 2017;174(1):1–6.
- 75 Deroux A, Dumestre-Perard C, Khalil-Mgharbel A, Maignan M, Boccon-Gibod I, Fevre MC, et al. BIOBRAD Study: The Search for Biomarkers of Bradykinin-Mediated Angio-Oedema Attacks. *Int Arch Allergy Immunol*. 2016;170(2):108–14.
- 76 Bork K, Witzke G. Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema. *Int Arch Allergy Immunol*. 2016;170(2):101–7.
- 77 Demirturk M, Akpınar TS, Kose M, Gelincik A, Colakoglu B, Buyukozturk S. Endocan: A Novel Marker of Endothelial Dysfunction in C1-Inhibitor-Deficient Hereditary Angioedema. *Int Arch Allergy Immunol*. 2017;174(2):104–7.
- 78 Gianni P, Loules G, Zamanakou M, Kompoti M, Csuka D, Psarros F, et al. Genetic determinants of C1 inhibitor deficiency angioedema age of onset. *Int Arch Allergy Immunol*. 2017;174(3-4):200–4.
- 79 Jung JW, Suh DI, Park HJ, Kim S, Kwon HS, Yang MS, et al. Clinical Features of Hereditary Angioedema in Korean Patients: A Nationwide Multicenter Study. *Int Arch Allergy Immunol*. 2018;176(3-4):272–9.
- 80 Aygören-Pürsün E, Soteres D, Moldovan D, Christensen J, Van Leerberghe A, Hao J, et al. Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings. *Int Arch Allergy Immunol*. 2017;173(2):114–9.
- 81 Pichler WJ, Hausmann O. Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. *Int Arch Allergy Immunol*. 2016;171(3-4):166–79.
- 82 Pichler WJ, Srinoulprasert Y, Yun J, Hausmann O. Multiple Drug Hypersensitivity. *Int Arch Allergy Immunol*. 2017;172(3):129–38.
- 83 Confino-Cohen R, Rosman Y, Lachover I, Meir Shafir K, Goldberg A. The Importance of Amoxicillin and Amoxicillin-Clavulanate Determinants in the Diagnosis of Immediate Allergic Reactions to β -Lactams. *Int Arch Allergy Immunol*. 2016;170(1):62–6.

- 84 Dibek Misirlioglu E, Guvenir H, Ozkaya Parlakay A, Toyran M, Tezer H, Catak AI, et al. Incidence of Antibiotic-Related Rash in Children with Epstein-Barr Virus Infection and Evaluation of the Frequency of Confirmed Antibiotic Hypersensitivity. *Int Arch Allergy Immunol*. 2018;176(1):33–8.
- 85 Sousa-Pinto B, Araújo L, Freitas A, Delgado L. Hospitalizations in Children with a Penicillin Allergy Label: An Assessment of Healthcare Impact. *Int Arch Allergy Immunol*. 2018;176(3-4):234–8.
- 86 Guvenir H, Dibek Misirlioglu E, Capanoglu M, Vezir E, Toyran M, Kocabas CN. Proven Non- β -Lactam Antibiotic Allergy in Children. *Int Arch Allergy Immunol*. 2016;169(1):45–50.
- 87 Guvenir H, Dibek Misirlioglu E, Capanoglu M, Buyuktiryaki B, Onay ZR, Ginis T, et al. The Frequency of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity in Children with Asthma. *Int Arch Allergy Immunol*. 2018;176(1):26–32.
- 88 Rebelo Gomes E, Gerales L, Gaspar Â, Malheiro D, Cadinha S, Abreu C, et al.; Portuguese Society of Allergology and Clinical Immunology (SPAIC) Drug Allergy Interest Group. Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs among Adults: Clinical Features and Risk Factors for Diagnosis Confirmation. *Int Arch Allergy Immunol*. 2016;171(3-4):269–75.
- 89 Al-Ahmad M, Rodriguez-Bouza T, Nurkic M. Establishing a Safe Administration of ASA in Cardiovascular Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity with Skin and/or Respiratory Involvement. *Int Arch Allergy Immunol*. 2018;175(4):237–45.
- 90 Blanca-López N, Pérez-Sánchez N, Agúndez JA, García-Martin E, Torres MJ, Cornejo-García JA, et al. Allergic Reactions to Metamizole: Immediate and Delayed Responses. *Int Arch Allergy Immunol*. 2016;169(4):223–30.
- 91 Gabrielli S, Langlois A, Ben-Shoshan M. Prevalence of Hypersensitivity Reactions in Children Associated with Acetaminophen: A Systematic Review and Meta-Analysis. *Int Arch Allergy Immunol*. 2018;176(2):106–14.
- 92 Spoerl D, D'Incau S, Roux-Lombard P, Harr T, Czarnetzki C. Non-IgE-Dependent Hypersensitivity to Rocuronium Reversed by Sugammadex: Report of Three Cases and Hypothesis on the Underlying Mechanism. *Int Arch Allergy Immunol*. 2016;169(4):256–62.
- 93 Cesana P, Scherer K, Bircher AJ. Immediate Type Hypersensitivity to Heparins: Two Case Reports and a Review of the Literature. *Int Arch Allergy Immunol*. 2016;171(3-4):285–9.
- 94 Karami Z, Mesdaghi M, Karimzadeh P, Mansouri M, Taghdiri MM, Kayhanidoost Z, et al. Evaluation of Lymphocyte Transformation Test Results in Patients with Delayed Hypersensitivity Reactions following the Use of Anticonvulsant Drugs. *Int Arch Allergy Immunol*. 2016;170(3):158–62.
- 95 Kepil Özdemir S, Öner Erkeköl F, Ünal D, Büyükoztürk S, Gelincik A, Dursun AB, et al. Management of Hypersensitivity Reactions to Proton Pump Inhibitors: A Retrospective Experience. *Int Arch Allergy Immunol*. 2016;171(1):54–60.
- 96 Bavbek S, Kendirlihan R, Çerçi P, Altınar S, Soyuyiğit Ş, Çelebi Sözen Z, et al. Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics. *Int Arch Allergy Immunol*. 2016;171(3-4):227–33.
- 97 Goh SH, Soh JY, Loh W, Lee KP, Tan SC, Heng WJ, et al. Cause and Clinical Presentation of Anaphylaxis in Singapore: From Infancy to Old Age. *Int Arch Allergy Immunol*. 2018;175(1-2):91–8.
- 98 Mosbech H, Tang L, Linneberg A. Insect Sting Reactions and Specific IgE to Venom and Major Allergens in a General Population. *Int Arch Allergy Immunol*. 2016;170(3):194–200.
- 99 Cardona V, Ferré-Ybarz L, Guilarte M, Moreno-Pérez N, Gómez-Galán C, Alcoceba-Borràs E, et al.; AdreSCAIC Research Group. Safety of Adrenaline Use in Anaphylaxis: A Multicentre Register. *Int Arch Allergy Immunol*. 2017;173(3):171–7.
- 100 Wang T, Ma X, Xing Y, Sun S, Zhang H, Stürmer T, et al. Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database. *Int Arch Allergy Immunol*. 2017;173(1):51–60.